Dr Reddy’s global generics revenue touch Rs 28.9 bn

Dr Reddy’s Laboratories announced its unaudited consolidated financial results for the quarter ended September 30, 2014 under International Financial Reporting Standards (IFRS)


(Photo Courtesy: www.thenextweb.com)

Key Highlights (Q2 FY15)

o Consolidated revenues at ₹35.9 billion, year-on-year growth of 7 percent.
• Revenues from the Global Generics (GG) segment at ₹28.9 billion, YoY growth of 9 percent
• Revenues from the Pharmaceutical Services and Active Ingredients (PSAI) segment at ₹6.4 billion.

o Gross Profit Margin at 58.5 percent versus 58.0 percent as in Q2 FY 14.

o Research and Development (R&D) expenses at ₹4.1 billion, 11.5 percent to revenues versus 9.0% to revenues as in Q2 FY14.

o Selling, general and administrative (SG&A) expenses at ₹10.7 billion, 29.7 percent to revenues.


Previous 1 3 4 5 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email